Beta-lactams in Sexually Transmitted Diseases: Rationale for Selection and Dosing Regimens

Overview

Journal Eur J Clin Microbiol

Specialty Microbiology

Date 1984 Dec 1

PMID 6098477

Citations 1

Authors

D Kunimoto

R Brunham

A Ronald

Affiliations

Soon will be listed here.

Abstract

A review is given of the selection and rational of optimal treatment regimens for patients with sexually transmitted pathogens, e.g. in cases of gonorrhea, chlamydial infections, chancroid, syphilis, pelvic inflammatory diseases and ophthalmia neonatorum. The scientific basis for the selection of a beta-lactam agent is discussed, including dose, MIC, the critical serum level and maintenance interval, and the duration of therapy. Except in the case of penicillinase-producing Neiserria gonorrhoeae, penicillin remained until recently the most effective agent available against many sexually transmitted diseases. However, ceftriaxone, a new third-generation cephalosporin, has been shown to have a long half-life (8 h) and excellent in vitro efficacy against Neiserria gonorrhoeae (including penicillinase-producing strains) and Haemophilis ducreyi. In view of its exceptional clinical efficacy against both gonorrhea and chancroid, clinical studies of its efficacy against other sexually transmitted diseases appear warranted.

Citing Articles

The value of new antimicrobial agents.

Wagenvoort J Eur J Clin Microbiol Infect Dis. 1993; 12 Suppl 1:S49-54.

PMID: 8477763 DOI: 10.1007/BF02389878.

References

Brunham R . Therapy for acute pelvic inflammatory disease: a critique of recent treatment trials. Am J Obstet Gynecol. 1984; 148(3):235-40. DOI: 10.1016/s0002-9378(84)80061-7. View

Handsfield H, Murphy V, Holmes K . Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men. Antimicrob Agents Chemother. 1981; 20(6):839-40. PMC: 181809. DOI: 10.1128/AAC.20.6.839. View

de Koning G, Tio D, van den Hoek J, van Klingeren B . Single 1 g dose of cefotaxime in the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeae. Br J Vener Dis. 1983; 59(2):100-2. PMC: 1046147. DOI: 10.1136/sti.59.2.100. View

KIRBY W, Regamey C . Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis. 1973; 128:Suppl:S341-6. DOI: 10.1093/infdis/128.supplement_2.s341. View

Bowie W, ALEXANDER E, Holmes K . Eradication of Chlamydia trachomatis from the urethras of men with nongonococcal urethritis by treatment with amoxicillin. Sex Transm Dis. 1981; 8(2):79-81. DOI: 10.1097/00007435-198104000-00010. View

SONNEVILLE P, Albert K, Skeggs H, Gentner H, Kwan K, Martin C . Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. Eur J Clin Pharmacol. 1977; 12(4):273-9. DOI: 10.1007/BF00607426. View

Handsfield H, Holmes K . Treatment of uncomplicated gonorrhea with cefotaxime. Sex Transm Dis. 1981; 8(3):187-91. DOI: 10.1097/00007435-198107000-00003. View

Glicksman J, SHORT D, Knox J . Parenteral cephaloridine treatment of patients with early syphilis. Arch Intern Med. 1968; 121(4):342-4. View

Ng W, Chau P, Arnold K . In vitro susceptibility of Haemophilus influenzae and neisseria gonorrhoeae to Ro 13-9904 in comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1981; 19(5):925-6. PMC: 181544. DOI: 10.1128/AAC.19.5.925. View

10.

Wiesner P, Handsfield H, Holmes K . Low antibiotic resistance of gonococci causing disseminated infection. N Engl J Med. 1973; 288(23):1221-2. DOI: 10.1056/NEJM197306072882308. View

11.

Fowler W, Rahim G, Brown J . Clinical experience in the use of cefuroxime in gonorrhoea. Br J Vener Dis. 1978; 54(6):400-2. PMC: 1045558. DOI: 10.1136/sti.54.6.400. View

12.

Karney W, Turck M, Holmes K . Single-dose oral therapy for uncomplicated gonorrhea: comparison of amoxicillin and ampicillin given with and without probenecid. J Infect Dis. 1974; 129(0):suppl:S250-8. DOI: 10.1093/infdis/129.supplement_2.s250. View

13.

Acred P, Grujic P, Ryan D, Xerri L, Orsolini P, Erani E . In vitro activity of cefuroxime against Treponema pallidum and Neisseria gonorrhoeae. J Antimicrob Chemother. 1980; 6(3):407-8. DOI: 10.1093/jac/6.3.407. View

14.

Zajdowicz T, Sanches P, Berg S, Kerbs S, Newquist R, HARRISON W . Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis. Br J Vener Dis. 1983; 59(3):176-8. PMC: 1046170. DOI: 10.1136/sti.59.3.176. View

15.

Leigh D, Le Franc J, Turnbull A . Sensitivity to penicillin of Neisseria gonorrhoeae. Relationship to the results of treatment. Br J Vener Dis. 1969; 45(2):151-3. PMC: 1048456. DOI: 10.1136/sti.45.2.151. View

16.

Eichmann A, WEIDMANN G, Havas L . One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order. Chemotherapy. 1981; 27 Suppl 1:62-9. DOI: 10.1159/000238031. View

17.

Patel I, Weinfeld R, Konikoff J, PARSONNET M . Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother. 1982; 21(6):957-62. PMC: 182052. DOI: 10.1128/AAC.21.6.957. View

18.

IDSOE O, Guthe T, WILLCOX R . Penicillin in the treatment of syphilis. The experience of three decades. Bull World Health Organ. 1972; 47 Suppl:1-68. PMC: 2480641. View

19.

Nsanze H, Fast M, DCosta L, Tukei P, Curran J, Ronald A . Genital ulcers in Kenya. Clinical and laboratory study. Br J Vener Dis. 1981; 57(6):378-81. PMC: 1045979. DOI: 10.1136/sti.57.6.378. View

20.

Stamm W, Guinan M, JOHNSON C, Starcher T, Holmes K, McCormack W . Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med. 1984; 310(9):545-9. DOI: 10.1056/NEJM198403013100901. View